Company Shares of Alder BioPharmaceuticals (NASDAQ:ALDR) Rally 4.05%

Alder BioPharmaceuticals (NASDAQ:ALDR) has been under a strong bear grip, hence the stock is down -11.07% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 2.73% in the past 1 week. The stock has risen by 4.05% in the past week indicating that the buyers are active at lower levels, but the stock is down -9.64% in the past 4 weeks.

The company shares have dropped -44.41% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $52.40 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $27.66 and the 200 Day Moving Average price is recorded at $25.66.

The stock has recorded a 20-day Moving Average of 2.22% and the 50-Day Moving Average is 0.43%.


Alder BioPharmaceuticals (NASDAQ:ALDR): stock turned positive on Friday. Though the stock opened at $26.6, the bulls momentum made the stock top out at $27.07 level for the day. The stock recorded a low of $26.07 and closed the trading day at $27, in the green by 1.58%. The total traded volume for the day was 618,390. The stock had closed at $26.58 in the previous days trading.

In an insider trading activity,The officer (Chief Business Officer) of Alder Biopharmaceuticals Inc, Litton Mark James sold 6,000 shares at $29.25 on June 13, 2016. The Insider selling transaction had a total value worth of $175,500. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Companys pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Companys monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushings disease.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.